Biomapas Appoints Chief Commercial Officer

By October 11, 2018 news2

Biomapas, a full service CRO with offices across central / eastern Europe and CIS countries, has been experiencing strong growth over the past few years. The company has recently appointed Chris Hamilton as Chief Commercial Officer. 

Audrius Sveikata, CEO of Biomapas, said, “We are delighted to have Chris Hamilton join the company. He is a strategic appointment for Biomapas and will play an important role in managing our continued growth.”

Chris has worked in international business development and marketing since 1999 and has been in the CRO sector since 2004. Aside from managing a business development and marketing team, he will work in a consultative way to help new and existing customers find solutions to their continuously-changing outsourcing needs. This may involve identifying the right expert to advise on a customer’s next steps in their development programme, filling a particular knowledge gap, implementing functional service provision, or providing a full outsource team for a clinical study. He holds a BA from Trinity College Dublin and a Diploma in Strategic Change Management from the Irish Management Institute.

 

About Biomapas

Biomapas is a privately owned contract research organization (CRO) providing comprehensive clinical trial solutions for Phase I-IV clinical research and medical devices.

With its strong foothold in Eastern Europe and CIS countries, the company has a superb track record in patient recruitment.  It is also well known for its extensive geographical reach in terms of on-the-ground regulatory and pharmacovigilance personnel. Biomapas employs an impressive team of experts, most of whom are either medical doctors (30%) or pharmacists (35%). With their diverse therapeutic expertise and thorough approach, they bring genuine value to Sponsors of clinical trials in terms of study design, regulatory support, study conduct and patient safety. The company has offices in Switzerland, Sweden, Lithuania, Georgia, Ukraine and Russia and has personnel in place to cover up to 64 countries.

Services range from first-in-human studies (with an impressive early phase unit in Vilnius, Lithuania) all the way up to product registration and post-approval support across Europe and CIS countries. Established in 2001, the company has gained experience of more than 190 clinical trials within numerous therapeutic fields including oncology, CNS, cardiovascular, infectious disease, immunology, rheumatology, pulmonology, endocrinology, gynecology, gastroenterology, nephrology, ophthalmology, urology and dermatology.